ImageneBio Grants Stock Awards to Three New Hires Under Nasdaq Rule
ImageneBio issued RSUs and stock options to three new non-executive employees as hiring incentives under Nasdaq Listing Rule 5635(c)(4).
ImageneBio, Inc. (Nasdaq: IMA) disclosed Thursday that its Board's Compensation Committee approved inducement equity grants to three newly hired non-executive employees on September 30, 2026, pursuant to Nasdaq Listing Rule 5635(c)(4), which permits companies to issue equity outside shareholder-approved plans as a material inducement to attract new talent.
The grants comprised 90,775 restricted stock units and 32,725 non-qualified stock options. Both award types are governed by the company's 2025 Equity Inducement Plan and accompanying award agreements, meaning they carry standard vesting schedules and forfeiture conditions typical of such arrangements.
Read more LODAS Markets, Nasdaq Complete First Interval Fund Auction for Harrison Street →
Inducement grants of this kind allow publicly traded companies to move quickly on competitive hiring without first seeking shareholder approval, a mechanism increasingly common in the biotech sector where talent competition is intense. Imagene, a San Diego-based biopharmaceutical company, did not disclose the specific roles filled or the individual vesting terms attached to the awards.
The announcement is a routine regulatory disclosure required by Nasdaq whenever a listed company issues equity under the inducement grant exemption, ensuring investor transparency about potential share dilution. The aggregate size of the grants represents a relatively modest equity commitment relative to typical biotech inducement packages.
Continue reading at GlobeNewswire - Industry News on Financial Services.
